Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 12/20 | 0.34 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.33 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14291808 | 0.85 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1TRAP1 | |
| SCHEMBL4580991 | 0.85 | HSP90AA1 (0.41) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4579610 | 0.84 | GAA (0.37) | HSP90AA1HSP90AB1 | |
| SCHEMBL4580707 | 0.82 | HSP90AA1 (0.45) | HSP90AA1HSP90AB1 | |
| SCHEMBL4582599 | 0.81 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1KCNH2 | |
| SCHEMBL4581622 | 0.79 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL4580729 | 0.79 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1 | |
| SCHEMBL1220975 | 0.67 | HSP90AA1 (0.67) | HSP90AA1HSP90AB1 | |
| SCHEMBL4580384 | 0.67 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1 | |
| SCHEMBL4578947 | 0.67 | HSP90AA1 (0.44) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | claimed |
| WO-2008024970-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | SERENEX, INC. | 2008-03-27 | — | — | US | disclosed |
| WO-2008024970-A2 | TETRAHYDROINDOLONE AND TETRAHYDROINDAZOLONE DERIVATIVES | SERENEX, INC. (US) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076813-A1 | Benzene, Pyridine, and Pyridazine Derivatives | MKI67, CCNB1, CCNB3 | HSP90AA1 2797/4885HSP90AB1 2208/4885HSP90B1 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.